胃癌组织中miR-29的表达及其临床意义

Expression of miR-29 in gastric cancer and its clinical significance

目的:研究胃癌组织中miR-29的表达情况及其与临床病理特征和预后的关系。方法:收集2005年至2010年中国人民解放军第324医院收治的进展期胃癌113例患者的手术标本,定量PCR检测胃癌组织及癌旁组织内miR-29的表达,并分析其与胃癌患者临床病理特征的关系。结果:胃癌组织内miR-29的表达显著低于对应的癌旁组织(2.62±1.17vs3.14±1.70,P=0.006),伴淋巴结转移的胃癌患者低表达miR-29百分率显著高于无淋巴结转移组(58.9%vs32.5%,P=0.007),miR-29低表达胃癌患者中位生存率显著低于miR-29高表达者(33.0vs44.0个月,P=0.013)。结论:胃癌组织低表达miR-29,miR-29有可能成为胃癌的预后判断指标及治疗靶标。

Objective：To explore the expression of miR-29 in gastric cancer and its relationship with clinic pathological features and prognosis of gastric cancer.Methods： Totally 113 gastric cancer samples were obtained from patients who received operation during 2005 to 2010 in the No.324 Hospital of PLA.The expression of miR-29 in gastric cancer and paracancerous tissues was detected by real-time PCR,and its relationship with clinic pathological features of gastric cancer was analyzed.Results： The expression of miR-29 in gastric cancer tissues was significantly lower than that in paracancerous tissues（2.62±1.17 vs 3.14±1.70,P=0.006）.The rate of low miR-29 expression in patients with lymph node metastases was significantly higher than that without lymph node metastases（58.9% vs 32.5%,P=0.007）.The median survival rate in low miR-29 expression cases was significantly lower than that in high miR-29 expression cases（33.0 vs 44.0 month,P=0.013）.Conclusion： miR-29 is lowly expressed in gastric cancer tissues,and it might be used for prediction of prognosis and as for targeted treatment of gastric cancer.